Business Description
Johnson & Johnson
NAICS : 325412
SIC : 2834
One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933
Compare
Compare
Traded in other countries / regions
JNJ.Argentina
•
JNJ.Austria
•
JNJB34.Brazil
•
JNJ.Chile
•
JNJ.Germany
•
JNJ.Mexico
•
JNJ.Peru
•
JNJ.Switzerland
•
0R34.UK
•
JNJ.USA
Description
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total revenue is generated in the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1 | |||||
| Equity-to-Asset | 0.43 | |||||
| Debt-to-Equity | 0.43 | |||||
| Debt-to-EBITDA | 1.18 | |||||
| Interest Coverage | 188.87 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 4.64 | |||||
| Beneish M-Score | -2.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.5 | |||||
| 3-Year EBITDA Growth Rate | 6.1 | |||||
| 3-Year EPS without NRI Growth Rate | 11.7 | |||||
| 3-Year FCF Growth Rate | 2.9 | |||||
| 3-Year Book Growth Rate | 7.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 4.28 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 3.32 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 9.34 | |||||
| 9-Day RSI | 21.59 | |||||
| 14-Day RSI | 30.82 | |||||
| 6-1 Month Momentum % | 18.97 | |||||
| 12-1 Month Momentum % | 18.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.42 | |||||
| Quick Ratio | 1.17 | |||||
| Cash Ratio | 0.73 | |||||
| Days Inventory | 126.65 | |||||
| Days Sales Outstanding | 58.65 | |||||
| Days Payable | 113.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.36 | |||||
| Dividend Payout Ratio | 0.63 | |||||
| 3-Year Dividend Growth Rate | 5.8 | |||||
| Forward Dividend Yield % | 2.72 | |||||
| 5-Year Yield-on-Cost % | 3.16 | |||||
| 3-Year Average Share Buyback Ratio | 0.4 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.86 | |||||
| Operating Margin % | 25.36 | |||||
| Net Margin % | 19.21 | |||||
| ROE % | 25.16 | |||||
| ROA % | 10.27 | |||||
| ROIC % | 17.38 | |||||
| ROC (Joel Greenblatt) % | 110.15 | |||||
| ROCE % | 15.15 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.33 | |||||
| Forward PE Ratio | 16.61 | |||||
| PE Ratio without NRI | 24.33 | |||||
| Shiller PE Ratio | 27.24 | |||||
| Price-to-Owner-Earnings | 24.93 | |||||
| PEG Ratio | 6.24 | |||||
| PS Ratio | 4.67 | |||||
| PB Ratio | 5.75 | |||||
| Price-to-Free-Cash-Flow | 22.38 | |||||
| Price-to-Operating-Cash-Flow | 18.93 | |||||
| EV-to-EBIT | 21.42 | |||||
| EV-to-Forward-EBIT | 14.58 | |||||
| EV-to-EBITDA | 15.87 | |||||
| EV-to-Forward-EBITDA | 13.01 | |||||
| EV-to-Revenue | 4.6 | |||||
| EV-to-Forward-Revenue | 4.58 | |||||
| EV-to-FCF | 22.03 | |||||
| Price-to-Projected-FCF | 1.73 | |||||
| Price-to-DCF (Earnings Based) | 1.93 | |||||
| Price-to-DCF (FCF Based) | 1.46 | |||||
| Price-to-Median-PS-Value | 1.01 | |||||
| Earnings Yield (Greenblatt) % | 4.67 | |||||
| Forward Rate of Return (Yacktman) % | 7.58 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 85,782.568 | ||
| EPS (TTM) (€) | 6.186 | ||
| Beta | 0.24 | ||
| Volatility % | 16.17 | ||
| 14-Day RSI | 30.82 | ||
| 14-Day ATR (€) | 1.936748 | ||
| 20-Day SMA (€) | 168.763 | ||
| 12-1 Month Momentum % | 18.6 | ||
| 52-Week Range (€) | 136.06 - 177.56 | ||
| Shares Outstanding (Mil) | 2,629.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Johnson & Johnson Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||